← Drug-vs-drug verdicts

Wegovy vs Foundayo: Weekly Injection or Daily Pill

Wegovy (semaglutide, Novo Nordisk) vs Foundayo (orforglipron, Eli Lilly)

Last verified May 2026

By Ruth Calder · Enforcement Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed

The verdict

STEP-1 reported −14.9% at 68 weeks for Wegovy; ATTAIN-1 reported −11.1% at 72 weeks for Foundayo. Close enough that delivery and cost may decide it — but Wegovy carries the completed cardiovascular outcome, MACE −20% in SELECT, and Foundayo has no MACE data yet. That is a real asymmetry rather than a footnote: one has been shown to prevent events, the other has been shown to reduce weight. Wegovy runs $349–$499 through NovoCare; Foundayo's pricing is still landing.

Side-by-side comparison

FieldWegovyFoundayo
Route & frequencySubcutaneous injection, once weeklyOral tablet, once daily — any time, with or without food
MechanismPeptide GLP-1 receptor agonist (semaglutide)Non-peptide small-molecule GLP-1 receptor agonist
Weight loss (pivotal trial, max dose)−14.9% TBWL / 68 wk (STEP-1, 2.4 mg)−11.1% body weight / 72 wk (ATTAIN-1, 17.2 mg)
FDA-approved indicationChronic weight management; CV risk reduction in obesity + CVDChronic weight management; type 2 diabetes
Dosing schedule0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly (5-step titration)0.8 → 1.6 → 3 → 5.5 → 9 → 14.5 → 17.2 mg daily (7-step titration)
Food / timing requirementNone (injectable)None — with or without food, any time of day
Whether a trial proved it prevents heart attacks and strokesSELECT cut major cardiac events 20% in obesity without diabetesNone. No outcomes trial has reported
What it costs if you pay cash$349-$499/mo through the manufacturer's direct-pay programDirect-pay pricing was still rolling out through 2026

What each one costs in the compounded market

Standing monthly cash prices from the 556 sellers on this register. These are compounded preparations, not the approved products compared above.

Wegovysemaglutide

from $79 /mo

283 sellers publish a standing price; the median is $174 a month.

Foundayoorforglipron

from $149 /mo

2 sellers publish a standing price; the median is $149 a month.

⚠ A compounded preparation is not the approved product. No agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed when the shortages closed. The price gap is real, and so is the difference in oversight. Every seller, with its price record.

Frequently asked questions

Which works better for weight loss, Wegovy or Foundayo?

Wegovy recorded −14.9% TBWL / 68 wk (STEP-1, 2.4 mg); Foundayo recorded −11.1% body weight / 72 wk (ATTAIN-1, 17.2 mg). ⚠ These come from separate trials with different protocols and populations, so the gap between two numbers from two studies is weaker evidence than it looks. No head-to-head trial of this pair is on record here.

Are Wegovy and Foundayo the same drug?

No. Wegovy is semaglutide and Foundayo is orforglipron — different molecules, and they work differently: Peptide GLP-1 receptor agonist (semaglutide) against Non-peptide small-molecule GLP-1 receptor agonist. Results with one do not predict results with the other.

Is Wegovy or Foundayo cheaper?

On the manufacturers' own cash pricing: Wegovy at $349-$499/mo through the manufacturer's direct-pay program, Foundayo at Direct-pay pricing was still rolling out through 2026. ⚠ That is the list-price comparison, and it is not what most people pay. What you actually pay depends on whether your plan covers it, which formulary tier it sits in, and whether you have met your deductible — and for many people the honest comparison is between an insured copay and a cash-pay compounded alternative rather than between these two figures.

How is each one taken?

Wegovy: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly (5-step titration). Foundayo: 0.8 → 1.6 → 3 → 5.5 → 9 → 14.5 → 17.2 mg daily (7-step titration). Worth weighing honestly against your own habits — the best drug for you is partly the one you will still be taking in eight months, and a dosing routine that does not fit a life gets abandoned.

What does a compounded version of each actually cost?

Across the 556 sellers in this register, the cheapest standing monthly cash prices we hold are semaglutide from $79 a month and orforglipron from $149 a month. ⛔ A compounded preparation is not the approved product: no agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed once the shortages closed. The price gap is real and so is the difference in oversight.

Can I switch from Wegovy to Foundayo?

Yes, with a prescriber. Expect to re-titrate from the bottom of the new drug's ladder rather than starting where you left off: these are different molecules and tolerance to one does not transfer to the other. Both the old drug's washout and the new drug's schedule apply.

Which one should I ask for?

That is a prescriber's call, and anyone answering it from a table is guessing. What a page like this can do is tell you what the trials measured, what the manufacturers charge, and where the evidence is still missing, so the conversation starts from the record rather than from an advertisement.

References

  1. 1.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID: 33567185.
  2. 2.Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). N Engl J Med. 2023. PMID: 37952131.
  3. 3.Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025. PMID: 40960239.
  4. 4.Wharton S, Blevins T, Connery L, et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity (Phase 2). N Engl J Med. 2023. PMID: 37351564.
  5. 5.Novo Nordisk. WEGOVY (semaglutide) injection — Prescribing Information. DailyMed (NIH/NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  6. 6.Eli Lilly and Company. FOUNDAYO (orforglipron) tablets — Prescribing Information. DailyMed (NIH/NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62

Related comparisons

See the full drug-vs-drug verdict index or provider rankings.